RANKL inhibition slows aging hallmarks in progeroid mice

Inhibiting RANKL, a key protein in bone remodeling, successfully reversed multiple aging markers in mice with Hutchinson-Gilford progeria syndrome, a genetic form of premature aging. Using either selective RANKL deletion in osteocytes or a neutralizing antibody, researchers restored bone mass in both long bones and vertebrae, substantially increased grip strength and endurance capacity, and extended lifespan in these animals. What stands out is that RANKL operates beyond bone tissue: its inhibition also reduced muscle fibrosis, indicating this protein plays a systemic role in aging across multiple mesenchymal tissues. Though these findings emerge from accelerated-aging models, they align with existing clinical data on bisphosphonates—drugs that inhibit osteoclasts via a different mechanism—showing survival advantages of up to five years in humans. For the longevity-curious reader, this signals a concrete therapeutic pathway: if RANKL inhibition works in normally aged mice, it could translate into a modifiable approach to preserve bone and muscle mass during aging.